Dr. Jonathan David Tward, MD, PhD

Dr. Tward practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Tward's NPI, 1144415969, was assigned on September 14, 2007. Dr. Tward graduated from Tufts University School of Medicine in 2003. Dr. Tward holds Utah license 5755988-1205.

Dr. Tward's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Tward's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Tward is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Tward to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tward practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Tward's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Tward is licensed in Utah.

CMS data shows 912 Medicare services from Dr. Tward across 15 procedure codes in 2024, for 216 Medicare patients. Medicare paid $80,632 for them.

CMS counts 216 Medicare patients who saw Dr. Tward in 2024. The largest group is 65 to 74, with 130 patients. 73% of them have cancer, and 63% have high blood pressure. Their average risk score is 1.50, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Tward's median patient age at 73, with 14% women.

In 2024, Dr. Tward wrote 181 Medicare Part D claims for 61 patients. 96% of them were for generic drugs. CMS names the drug for 149 of them, across 4 drugs with 11 or more claims each, at $2,419 in total drug cost. In 2023, CMS named 167 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Tward for performance year 2024, reported as part of a group. Dr. Tward accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Tward as offering telehealth.

Dmand AI links 86 papers to Dr. Tward, published from 2007 to 2025. 2021 was the busiest year, with 13. The most frequent topics are Prostatic Neoplasms, Prostatectomy and Androgen Antagonists. Dr. Tward has published most often in Clin Genitourin Cancer. Dr. Tward's most frequent co-authors are Dennis C. Shrieve, MD, Christopher Burr Dechet, MD and David K. Gaffney, MD, PhD.

Dmand AI links Dr. Tward to 6 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Urinary Bladder Neoplasms and Prostatic Diseases. NRG Oncology sponsors the most, 2.

CMS Open Payments shows 182 general payments to Dr. Tward from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 72% of the total. Myriad Genetic Laboratories, Inc. paid the most, $36,776.

Dr. Tward graduated from Tufts University School of Medicine in 2003.